Q-omics provides the consensus-scored RPS15AP9 profile across patient tissues and cancer cell-line models. RPS15AP9 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPS15AP9 is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, RPS15AP9 RNA expression shows 7,900 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight ACC, BRCA, and LIHC as cancer lineages where RPS15AP9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS15AP9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS15AP9 survival associations across molecular data types. RPS15AP9 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS15AP9 RNA expression–survival associations across cancer types. High RPS15AP9 expression shows unfavorable associations in ACC, THYM, LUAD, KIRP and LGG, but favorable associations in CESC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify ACC as the clearest survival context for RPS15AP9 RNA expression.
This table summarizes RPS15AP9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPS15AP9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS15AP9 shows lower tumor expression in BRCA and KIRC and higher tumor expression in LUAD, CHOL and LUSC. The BRCA box plot shows higher RPS15AP9 RNA expression in normal versus tumor tissue (log2 FC = −0.258, t-test p = .022).
This table shows molecular features associated with RPS15AP9 in patient tissues and cancer cell lines. In patient samples, RPS15AP9 shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set.
